Aussie patient groups get vocal on pricing
New website reveals that Australian patients are among the most active in the world when it comes to taking their case for medicines access to drug-pricing regulators
New website reveals that Australian patients are among the most active in the world when it comes to taking their case for medicines access to drug-pricing regulators
An Australian company is helping time-poor doctors stay up to speed with the latest research by turning clinical papers into podcasts with pharmas on board as sponsors
This ASX-listed company has increased its stake to own two-thirds of a joint venture started two years ago but investors are not impressed
The US President has come under scrutiny after boosting his pharma shareholdings by a breathtaking 3000 per cent last year. Find out which companies he's invested in and why it's caused controversy
Among the 15-strong list are nine drugs vying to become the first to secure subsidy after being recommended at the PBAC's July 2026 meeting
Medicines Australia has named two high-profile company leaders as the newest additions to the Board, after Country Leadership changes mid-year resulted in departures
The deal sees Roche take over late stage development and gain ex-China marketing rights for a range of ADCs.
The TGA has handed out eight orphan drug designations in the past quarter, with three of them targeting the same kidney disease.
One submission withdrawn, a couple of newcomers join the list and a potentially eye-opening DUSC analysis deferred as PBAC readies for its next meeting in a fortnight
A high-profile former Senior Health Department official turned patient advocate has called on the pharmaceutical industry to force the Government to take HTA reform seriously by withholding all submissions from the PBAC
Two out of three companies hoping to cut a path to a broad listing were told the preliminary info they provided didn't cut it, according to outcomes from September's Intracycle Meeting
A bitter court battle is heating up with two companies now accusing each other of misleading advertising over claims about side effects and speed of absorption
A second company has registered a copycat of a cancer drug across all tablet blister strengths, turning up the heat on the originator brand
A report released by the ATO has revealed the total income declared in Australia for all pharmas who brought in at least a hundred million dollars. See the list
Product information updates for two jabs after reports of incorrect preparation and administration, which may result in the recall of patients for re-vaccination
Five companies have splashed cash on new assets to build out their current portfolios, with one hoping a Virtual Human AI platform will uncover transformative therapeutics
The PBAC has updated the guidelines for pharmas seeking multi-cancer listings, looking for information beyond the clinical
After 30 years working in innovative medicine companies, the decision for Nikki Lorenz to become a champion of the generics and biosimilars industry was a surprisingly easy one
While this pharma has staved off a potentially hefty fine, it has agreed to a tough, legally binding agreement after an EU antitrust case
Recognised as a Great Place to Work for the fifth time, this company blitzed the benchmarks across four measures with a standout result for celebrating special events.
A strategy to protect market share for this oncology juggernaut has run into a major roadblock overseas and the same legal hurdle could hit Australia too
Following reports of eight deaths overseas, allegations trial results were manipulated plus regulatory action in the UK and Europe, this drug is coming off the market
GSK's Australian Country Leader Andrew Thomas tells how being open to 'taking a shot' created a global high-flying career and offers tips on how pharma professionals can get ahead, in a new book called Work Fame
A US company is ramping up its Australian commercialisation efforts for a gene therapy that won the Best Product for Orphan Disease at the 2026 Prix Galien UK Awards
Exactly one year after the late Professor challenged Australia to bring the same ambition to brain cancer that helped transform advanced melanoma, advocates are back at Parliament House
A UCB-sponsored report into the failings of paediatric medicine funding was launched in Parliament House today, attended by the heads of the Standing Committee on Health